|
1
|
Aronson D and Edelman ER: Coronary artery
disease and diabetes mellitus. Cardiol Clin. 32:439–455. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pagidipati NJ and Peterson ED: Acute
coronary syndromes in women and men. Nat Rev Cardiol. 13:471–480.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lusis AJ: Atherosclerosis. Nature.
407:233–241. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosenfeld ME, Polinsky P, Virmani R,
Kauser K, Rubanyi G and Schwartz SM: Advanced atherosclerotic
lesions in the innominate artery of the ApoE knockout mouse.
Arterioscler Thromb Vasc Biol. 20:2587–2592. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schonbeck U and Libby P: CD40 signaling
and plaque instability. Circ Res. 89:1092–1103. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rajagopalan S, Meng XP, Ramasamy S,
Harrison DG and Galis ZS: Reactive oxygen species produced by
macrophage-derived foam cells regulate the activity of vascular
matrix metalloproteinases in vitro. Implications for
atherosclerotic plaque stability. J Clin Invest. 98:2572–2579.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabunmi RP, Moore KJ, Libby P and Freeman
MW: Stromelysin-1 (MMP-3) expression driven by a
macrophage-specific promoter results in reduced viability in
transgenic mice. Atherosclerosis. 148:375–386. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Major TC, Liang L, Lu X, Rosebury W and
Bocan TM: Extracellular matrix metalloproteinase inducer (EMMPRIN)
is induced upon monocyte differentiation and is expressed in human
atheroma. Arterioscler Thromb Vasc Biol. 22:1200–1207. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patti G, Pasceri V, Colonna G, Miglionico
M, Fischetti D, Sardella G, Montinaro A and Di Sciascio G:
Atorvastatin pretreatment improves outcomes in patients with acute
coronary syndromes undergoing early percutaneous coronary
intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll
Cardiol. 49:1272–1278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soeda T, Uemura S, Okayama S, Kawakami R,
Sugawara Y, Nakagawa H, Matsumoto T, Sung JH, Nishida T, Senoo A,
et al: Intensive lipid-lowering therapy with rosuvastatin
stabilizes lipid-rich coronary plaques. -Evaluation using
dual-source computed tomography. Circ J. 75:2621–2627. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murphy SA, Cannon CP, Wiviott SD, de Lemos
JA, Blazing MA, McCabe CH, Califf RM and Braunwald E: Effect of
intensive lipid-lowering therapy on mortality after acute coronary
syndrome (a patient-level analysis of the Aggrastat to Zocor and
Pravastatin or Atorvastatin Evaluation and Infection
Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J
Cardiol. 100:1047–1051. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Farmer JA and Gotto AM Jr: Currently
available hypolipidaemic drugs and future therapeutic developments.
Baillieres Clin Endocrinol Metab. 9:825–847. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Illingworth DR and Bacon S: Hypolipidemic
effects of HMG-CoA reductase inhibitors in patients with
hypercholesterolemia. Am J Cardiol. 60:33G–42G. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Driscoll G, Green D and Taylor RR:
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves
endothelial function within 1 month. Circulation. 95:1126–1131.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stroes ES, Koomans HA, de Bruin TW and
Rabelink TJ: Vascular function in the forearm of
hypercholesterolaemic patients off and on lipid-lowering
medication. Lancet. 346:467–471. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meredith IT, Plunkett JC, Worthley SG,
Hope SA and Cameron JD: Systemic inflammatory markers in acute
coronary syndrome: Association with cardiovascular risk factors and
effect of early lipid lowering. Coron Artery Dis. 16:415–422. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ridker PM: Inflammation, infection, and
cardiovascular risk: How good is the clinical evidence?
Circulation. 97:1671–1674. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Williams H, Johnson JL, Carson KG and
Jackson CL: Characteristics of intact and ruptured atherosclerotic
plaques in brachiocephalic arteries of apolipoprotein E knockout
mice. Arterioscler Thromb Vasc Biol. 22:788–792. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Burke AP, Farb A, Malcom GT, Liang YH,
Smialek J and Virmani R: Coronary risk factors and plaque
morphology in men with coronary disease who died suddenly. N Engl J
Med. 336:1276–1282. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Virmani R, Burke A and Farb A: Coronary
risk factors and plaque morphology in men with coronary disease who
died suddenly. Eur Heart J. 19:678–680. 1998.PubMed/NCBI
|
|
22
|
Biswas C, Zhang Y, DeCastro R, Guo H,
Nakamura T, Kataoka H and Nabeshima K: The human tumor cell-derived
collagenase stimulatory factor (renamed EMMPRIN) is a member of the
immunoglobulin superfamily. Cancer Res. 55:434–439. 1995.PubMed/NCBI
|
|
23
|
Schmidt R, Bültmann A, Ungerer M,
Joghetaei N, Bülbül O, Thieme S, Chavakis T, Toole BP, Gawaz M,
Schömig A and May AE: Extracellular matrix metalloproteinase
inducer regulates matrix metalloproteinase activity in
cardiovascular cells: Implications in acute myocardial infarction.
Circulation. 113:834–841. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong
BK, Kim D, Kim HS, Cho SH, Song KS and Sangiorgi G: Upstream
regulation of matrix metalloproteinase by EMMPRIN; Extracellular
matrix metalloproteinase inducer in advanced atherosclerotic
plaque. Atherosclerosis. 180:37–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ghattas A, Griffiths HR, Devitt A, Lip GY
and Shantsila E: Monocytes in coronary artery disease and
atherosclerosis: Where are we now? J Am Coll Cardiol. 62:1541–1551.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen F, Eriksson P, Hansson GK, Herzfeld
I, Klein M, Hansson LO and Valen G: Expression of matrix
metalloproteinase 9 and its regulators in the unstable coronary
atherosclerotic plaque. Int J Mol Med. 15:57–65. 2005.PubMed/NCBI
|
|
27
|
Nakashima Y, Plump AS, Raines EW, Breslow
JL and Ross R: ApoE-deficient mice develop lesions of all phases of
atherosclerosis throughout the arterial tree. Arterioscler Thromb.
14:133–140. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jawien J, Nastalek P and Korbut R: Mouse
models of experimental atherosclerosis. J Physiol Pharmacol.
55:503–517. 2004.PubMed/NCBI
|
|
29
|
Johnson J, Carson K, Williams H, Karanam
S, Newby A, Angelini G, George S and Jackson C: Plaque rupture
after short periods of fat feeding in the apolipoprotein E-knockout
mouse: Model characterization and effects of pravastatin treatment.
Circulation. 111:1422–1430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rosenfeld ME, Carson KG, Johnson JL,
Williams H, Jackson CL and Schwartz SM: Animal models of
spontaneous plaque rupture: The holy grail of experimental
atherosclerosis research. Curr Atheroscler Rep. 4:238–242. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao P, Guo RW, Chen JF, Chen Y, Wang H, Yu
Y and Huang L: A meprin inhibitor suppresses atherosclerotic plaque
formation in ApoE−/− mice. Atherosclerosis. 207:84–92.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng XW, Kuzuya M, Sasaki T, Arakawa K,
Kanda S, Sumi D, Koike T, Maeda K, Tamaya-Mori N, Shi GP, et al:
Increased expression of elastolytic cysteine proteases, cathepsins
S and K, in the neointima of balloon-injured rat carotid arteries.
Am J Pathol. 164:243–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grainger DJ, Witchell CM and Metcalfe JC:
Tamoxifen elevates transforming growth factor-beta and suppresses
diet-induced formation of lipid lesions in mouse aorta. Nat Med.
1:1067–1073. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sukhova GK, Zhang Y, Pan JH, Wada Y,
Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML, et
al: Deficiency of cathepsin S reduces atherosclerosis in LDL
receptor-deficient mice. J Clin Invest. 111:897–906. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang J, Ge H, Wang C, Guo TB, He Q, Shao
Q and Fan Y: Inhibitory effect of PPAR on the expression of EMMPRIN
in macrophages and foam cells. Int J Cardiol. 117:373–380. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seizer P, Schonberger T, Schött M, Lang
MR, Langer HF, Bigalke B, Krämer BF, Borst O, Daub K, Heidenreich
O, et al: EMMPRIN and its ligand cyclophilin A regulate MT1-MMP,
MMP-9 and M-CSF during foam cell formation. Atherosclerosis.
209:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gabison EE, Hoang-Xuan T, Mauviel A and
Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development
and tissue repair. Biochimie. 87:361–368. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Haug C, Lenz C, Díaz F and Bachem MG:
Oxidized low-density lipoproteins stimulate extracellular matrix
metalloproteinase Inducer (EMMPRIN) release by coronary smooth
muscle cells. Arterioscler Thromb Vasc Biol. 24:1823–1829. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dutta P, Courties G, Wei Y, Leuschner F,
Gorbatov R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T,
et al: Myocardial infarction accelerates atherosclerosis. Nature.
487:325–329. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kampoli AM, Tousoulis D, Papageorgiou N,
Antoniades C, Androulakis E, Tsiamis E, Latsios G and Stefanadis C:
Matrix metalloproteinases in acute coronary syndromes: Current
perspectives. Curr Top Med Chem. 12:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Satoh K, Nigro P, Matoba T, O'Dell MR, Cui
Z, Shi X, Mohan A, Yan C, Abe J, Illig KA and Berk BC: Cyclophilin
A enhances vascular oxidative stress and the development of
angiotensin II-induced aortic aneurysms. Nat Med. 15:649–656. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sukhanov S, Higashi Y, Shai SY, Vaughn C,
Mohler J, Li Y, Song YH, Titterington J and Delafontaine P: IGF-1
reduces inflammatory responses, suppresses oxidative stress, and
decreases atherosclerosis progression in ApoE-deficient mice.
Arterioscler Thromb Vasc Biol. 27:2684–2690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Newby AC: Metalloproteinases and
vulnerable atherosclerotic plaques. Trends Cardiovasc Med.
17:253–258. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nie R, Xie S, Du B, Liu X, Deng B and Wang
J: Extracellular matrix metalloproteinase inducer (EMMPRIN) is
increased in human left ventricle after acute myocardial
infarction. Arch Med Res. 40:605–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fiotti N, Altamura N, Orlando C, Simi L,
Reimers B, Pascotto P, Zingone B, Pascotto A, Serio M, Guarnieri G
and Giansante C: Metalloproteinases-2, −9 and TIMP-1 expression in
stable and unstable coronary plaques undergoing PCI. Int J Cardiol.
127:350–357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang LX, Yang ZH, Guo RW, Ye JS and Liu H:
Angiotensin II induces extracellular matrix metalloproteinase
inducer expression via an AT1R dependent pathway in aortic
atherosclerotic plaque in apolipoprotein E knockout mice. J Renin
Angiotensin Aldosterone Syst. 13:67–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bea F, Blessing E, Bennett B, Levitz M,
Wallace EP and Rosenfeld ME: Simvastatin promotes atherosclerotic
plaque stability in apoE-deficient mice independently of lipid
lowering. Arterioscler Thromb Vasc Biol. 22:1832–1837. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ray KK and Cannon CP: Atorvastatin and
cardiovascular protection: A review and comparison of recent
clinical trials. Expert Opin Pharmacother. 6:915–927. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shao Q, Shen LH, Hu LH, Pu J, Jing Q and
He B: Atorvastatin suppresses inflammatory response induced by
oxLDL through inhibition of ERK phosphorylation, IκBα degradation,
and COX-2 expression in murine macrophages. J Cell Biochem.
113:611–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Deng P, Zhao SP, Dai HY, Guan XS and Huang
HG: Atorvastatin reduces the expression of COX-2 mRNA in peripheral
blood monocytes from patients with acute myocardial infarction and
modulates the early inflammatory response. Clin Chem. 52:300–303.
2006. View Article : Google Scholar : PubMed/NCBI
|
